SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is witnessing significant volatility amid recent CME margin hikes and widespread discussions surrounding upcoming Chinese export restrictions. The community is sharply divided between bullish investors anticipating an explosive rally driven by industrial demand and supply concerns, and bearish traders who warn of a speculative "pump and dump" and an unsustainable price bubble. This fierce debate highlights the ongoing battle between paper market dynamics and long-term fundamental perspectives.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its position as 'Bitcoin's Digital Silver Cousin' draws significant retail attention, with recent news highlighting its market performance. The community is buzzing with anticipation, discussing upcoming developments like the LitVM airdrop and technical chart setups, even as some express frustration over persistent resistance levels. Sentiment remains divided between those expecting a major breakout and those observing market manipulation, while also noting its enhanced privacy features with MWEB and Omnichain.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is trending as its dedicated 'DOG Army' passionately advocates for its position as the leading Bitcoin-native memecoin, highlighting its unique permanence and direct link to Bitcoin's infrastructure. Community discussion is amplified by news of companies like C2 Blockchain ($CBLO) significantly expanding their $DOG treasury holdings, signaling growing institutional interest and long-term conviction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to its preemptive release of Q4 delivery estimates, which are below Wall Street's consensus, fueling intense debate on its sales trajectory. Bulls are betting on a significant short squeeze, highlighting massive options activity and the long-term potential of Tesla Energy and autonomous driving technologies. Conversely, bears are expressing alarm over declining core auto sales, dismissing future promises as vaporware, and reiterating concerns about the stock's elevated valuation.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is trending as its inclusion in the Russell indexes vies for attention with persistent selling pressure, largely attributed to ongoing dilution from SPAC-related share agreements and year-end portfolio adjustments. Community sentiment is deeply divided, with optimists emphasizing the company's profitability and long-term growth potential, while skeptics highlight continuous price declines and concerns over further share dilution. This divergence underscores broader market debates on fintech valuations and the impact of SPAC-originated supply on stock performance.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for NEREUS (tradipitant), marking the first new motion sickness drug in approximately 40 years. The community is highly engaged, primarily discussing the drug's significant potential as an add-on treatment for GLP-1 induced nausea, fueling widespread speculation of a substantial buyout from major pharmaceutical players. This pivotal approval, alongside other imminent pipeline catalysts, has many anticipating significant long-term growth despite initial market fluctuations.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics ($EKSO) is seeing a significant surge and exceptional trading volume following news of a proposed business combination with Applied Digital's Cloud business to form ChronoScale Corporation, focused on AI workloads. The community is actively debating the implications of this AI infrastructure play, with many highlighting its low float and anticipating further momentum from short squeezes. However, some voices express caution regarding potential dilution for existing shareholders and the long-term outlook of the combined entity.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid a significant surge in silver prices, fueled by increasing industrial demand and speculation that silver is playing catch-up with gold's rally. The community is buzzing with predictions of further explosive gains and a 'silver squeeze,' though some express caution about extreme volatility and the potential for a sharp correction in this leveraged commodity.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending due to escalating controversy surrounding a significant data breach impacting millions of users and its perceived lack of transparency, drawing strong criticism from both Korean government officials and consumers. The community is vigorously discussing leadership's response and the potential for severe operational and financial repercussions, as mounting calls for boycotts and legal action cast a shadow over its future in its dominant market.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is actively trending amid widespread community discussion anticipating aggressive Fed rate cuts and potential quantitative easing, which some believe will further debase the dollar and fuel inflation. This outlook, combined with escalating global trade tensions and signs of economic fragility despite a rising equity market, is driving significant interest in gold and related mining assets as a perceived safe haven.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Equity

Shares of Poseida Therapeutics Inc. (<a class="mention" data-mention="$PSTX" data-symbol-id="PSTX" href="https://stocktwits.com/symbol/PSTX" target="_blank">$PSTX</a>) surged over 200% on Tuesday, reaching levels not seen since August 2021, after the company announced its acquisition by Roche Holdings ($RHHBY) in a deal valued at up to $1.5 billion.The stock was the top gainer across U.S. markets early on Tuesday and was among the top 10 trending symbols on Stocktwits.Under the agreement, Poseida stockholders will receive $9.00 per share in cash at closing, along with a non-tradable contingent value right (CVR) of up to $4.00 per share, contingent upon achieving specific milestones.&nbsp;The deal underscores Roche’s interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory (TSCM) cells.“Poseida has demonstrated the unique ability of its proprietary non-viral technology platform to create allogeneic, TSCM-rich CAR-T therapies with the potential to improve clinical outcomes and expand access to this important class of medicines,” said Poseida CEO Kristin Yarema.“Most recently, this was highlighted by the compelling interim clinical data for P-BCMA-ALLO1 in patients with multiple myeloma.”Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.Wall Street analysts reportedly responded with several downgrades for Poseida, citing the definitive valuation set by the acquisition terms.H.C. Wainwright, William Blair, BTIG, and Cantor Fitzgerald all downgraded the stock to ‘Neutral’ or equivalent ratings, noting the fair terms of the $13 per share offer, which includes both upfront cash and milestone-dependent payouts.The acquisition builds on a collaboration between the two companies that began in 2022, focused on CAR-T cell therapies for hematologic malignancies.&nbsp;The merger is expected to close in the first quarter of 2025, with Poseida and its employees set to join Roche’s Pharmaceuticals Division.Retail sentiment on Stocktwits has also turned ‘extremely bullish’, with users highlighting the premium payout as a significant win for shareholders.<stembedurl>https://stocktwits.com/lecorb/message/594107339</stembedurl><stembedurl>https://stocktwits.com/symbol/PSTX</stembedurl>Poseida shares, which had lost over 15% year-to-date before the announcement, are now poised for a dramatic turnaround, driven by investor optimism about the acquisition.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intc-stock-rises-on-finalizing-chips-act-funding/cJIWnjbRgs">Intel Stock Rises As Chipmaker Secures $7.9B CHIPS Act Funding From Team Biden: Retail Hopes Improve</a>

Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.

Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric

The deal underscores Roche's interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory cells.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

PSTX
Poseida Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTX News

PSTXPoseida Therapeutics Inc